Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Performance of 68Ga-SGC8 in Colorectal Cancer
NCT03385148Phase 1Unknown
- Sponsor
- Xijing Hospital
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NOTA-SGC8 in colorectal cancer (CRC), sponsored by Xijing Hospital. Primary endpoint: Diagnostic Efficacy at 2 years. Status: unknown.
02
Drugs
68Ga-NOTA-SGC8
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03385148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385148.